Drugs / DVX201
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04901416 | Dec 2021 → Oct 2023 | acute myeloid leukemia, myelodysplastic syndrome | Coeptis Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT04900454 | Aug 2021 → Jun 2022 | pneumonia | Coeptis Therapeutics | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-11-07 | Coeptis Therapeutics | Results Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical Development coeptis.com ↗
Results from the clinical trial demonstrated the safety and feasibility of DVX201 as a potential treatment for patients with active SARS-CoV-2 infections. |
| 2023-09-14 | Coeptis Therapeutics | Results Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 Infection coeptis.com ↗
Interim data from both trials involving 16 patients and 23 infusions of DVX201 indicate that the NK cell therapy is well-tolerated with no dose limiting toxicities (DLTs), cytokine release syndrome (CRS) or infusion toxicities observed thus far through the highest dose level. |
All press releases naming this drug 2 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DVX201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04900454 ↗ |
| Known as | DVX201-S | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095332 ↗ |
| Modality | Cell therapy | “DVX201 is an allogeneic NK (natural killer) cell therapy.” NCT04900454 ↗ |